SCOLR IND
This article was originally published in The Tan Sheet
Executive Summary
Bellevue, Wash.-based firm has submitted an investigational new drug application with FDA in advance of conducting studies on extended-release ibuprofen in humans, the firm announces. The trial is slated to begin in early 2005, with an NDA submission planned for the summer, SCOLR adds. The firm initially aimed to begin human trials in Canada this fall (1"The Tan Sheet" Aug. 2, 2004, p. 12)...
You may also be interested in...
Ibuprofen Extended-Release NDA Slated For 2005, SCOLR Pharma Says
SCOLR Pharma plans to file an NDA in summer 2005 for CDT extended-release 12-hour ibuprofen tablets, the firm announced July 26
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.